Research programme: lysosphingolipid receptor agonists - Amgen/EPIXAlternative Names: AMG 277; PRX-13038; S1P1 agonists - EPIX
Latest Information Update: 07 Oct 2011
At a glance
- Originator EPIX Pharmaceuticals
- Developer Amgen; EPIX Pharmaceuticals
- Mechanism of Action Lysosphingolipid receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Autoimmune disorders; Cancer